Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase III"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Preclinical"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Suggests the Use of OraPharma\u2019s ARESTIN\u00ae (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Approved"}]

    Find Clinical Drug Pipelines for Dental and Oral Health

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Study Phase
            filter Product Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Development Status

              ORAPHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

              Details:

              ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

              Lead Product(s): Minocycline Hydrochloride

              Therapeutic Area: Dental and Oral Health Product Name: Arestin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch Health

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RxOMEG Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

              Details:

              Pilocarpine is a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiotherapy.

              Lead Product(s): Pilocarpine Hydrochloride

              Therapeutic Area: Dental and Oral Health Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ASEP Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market

              Details:

              The agreement permits Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient. The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an oral rinse product.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dental and Oral Health Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Bohai Biomedical Technology Development Co.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Locust Walk

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

              Details:

              This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.

              Lead Product(s): Brilacidin

              Therapeutic Area: Dental and Oral Health Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Innovation Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY